Absence of BK viremia clearance after low-dose cidofovir therapy in kidney transplant recipients with BK virus associated nephropathy
Details
Serval ID
serval:BIB_B5A6F5250878
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Absence of BK viremia clearance after low-dose cidofovir therapy in kidney transplant recipients with BK virus associated nephropathy
Title of the conference
Abstracts of the 15th International Symposium on Infections in the Immunocompromised Host
Address
Thessaloniki, Greece, June 22-25, 2008
ISBN
1201-9712
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
12
Series
International Journal of Infectious Diseases
Pages
S12-S13
Language
english
Abstract
Background: BK virus associated nephropathy occurs in 1-10% of
kidney transplant recipients and may be a cause of graft loss. This
infection is difficult to manage because of the absence of specific
therapy. Cidofovir, a DNA polymerase inhibitor approved for the
treatment of CMV retinitis, has shown in vitro activity against BK
virus and some clinical efficacy when used at low-dose in uncontrolled
series.
Objective: To assess the efficacy of low-dose Cidofovir in the treatment
of BK virus associated nephropathy.
Method: Two adult kidney transplant recipients with biopsy-proven
BK nephropathy and persistent high viremia (>10,000 copies/ml)
despite 3-month reduction of immunosuppressive therapy were
treated by Cidofovir 0.5 mg/kg fortnightly for a total of 16 weeks
(8 doses). Clinical response was assessed by following BK viremia.
Results: No decrease in BK viremia was observed at any point during
cidofovir therapy (see figure). Creatinine clearance remained
stable during therapy and no side-effects of Cidofovir were observed.
Conclusions: Low-dose Cidofovir therapy was not associated with
a clearance or with a significant decrease of BK viremia. This pilot
study does not confirm previous reports suggesting clinical efficacy
of Cidofovir for BK virus associated nephropathy.
kidney transplant recipients and may be a cause of graft loss. This
infection is difficult to manage because of the absence of specific
therapy. Cidofovir, a DNA polymerase inhibitor approved for the
treatment of CMV retinitis, has shown in vitro activity against BK
virus and some clinical efficacy when used at low-dose in uncontrolled
series.
Objective: To assess the efficacy of low-dose Cidofovir in the treatment
of BK virus associated nephropathy.
Method: Two adult kidney transplant recipients with biopsy-proven
BK nephropathy and persistent high viremia (>10,000 copies/ml)
despite 3-month reduction of immunosuppressive therapy were
treated by Cidofovir 0.5 mg/kg fortnightly for a total of 16 weeks
(8 doses). Clinical response was assessed by following BK viremia.
Results: No decrease in BK viremia was observed at any point during
cidofovir therapy (see figure). Creatinine clearance remained
stable during therapy and no side-effects of Cidofovir were observed.
Conclusions: Low-dose Cidofovir therapy was not associated with
a clearance or with a significant decrease of BK viremia. This pilot
study does not confirm previous reports suggesting clinical efficacy
of Cidofovir for BK virus associated nephropathy.
Web of science
Open Access
Yes
Create date
14/10/2009 12:20
Last modification date
20/08/2019 15:24
Usage data
